Core Viewpoint - Phio Pharmaceuticals Corp. has announced the exercise of warrants that will generate approximately $13.4 million in gross proceeds, aimed at advancing its clinical development activities for its lead product, PH-762, targeting skin cancers [1][4]. Group 1: Warrant Exercise Details - The company has entered into agreements to exercise warrants for a total of 5,663,182 shares of common stock, with exercise prices ranging from $2.00 to $5.45 per share [1]. - The exercise includes 60,000 shares at $2.00, 948,596 shares at $2.485, and 4,654,586 shares at a reduced price of $2.05 [1]. - The gross proceeds from these exercises are expected to be around $13.4 million before deducting fees and expenses [1]. Group 2: New Warrants and Offerings - In exchange for the immediate cash exercise of the warrants, holders will receive new unregistered warrants to purchase up to 8,855,248 shares of common stock [3]. - The offering will occur in two closings, with the first expected on or about November 4, 2025, and the second by November 18, 2025 [3]. - The new warrants will have an exercise price of $2.05 per share and will be immediately exercisable for a term of twenty-four months [3]. Group 3: Use of Proceeds - The net proceeds from the warrant exercises will primarily be used for working capital and to accelerate the completion of development activities for PH-762, following positive trial outcomes [4]. Group 4: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics, utilizing its INTASYL® gene silencing technology [8]. - The lead clinical program, PH-762, targets the PD-1 gene and is currently in a Phase 1b trial for treating various skin cancers [8].

Core Insights - Phio Pharmaceuticals has appointed Mr. David H. Deming as Lead Independent Director, bringing over 30 years of experience in investment banking and asset management to the role [1][2][3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program is PH-762, which targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Leadership Experience - Mr. Deming has a significant background in investment banking, having spent over 27 years at JP Morgan, where he led the Health Group in investment banking for the last 12 years of his tenure [2] - His experience in the biopharma sector and corporate boards is expected to provide valuable insights as Phio advances its gene silencing technology [3]

Core Viewpoint - Phio Pharmaceuticals Corp. has announced the exercise of warrants that will generate approximately $2.5 million in gross proceeds, aimed at supporting its clinical-stage siRNA biopharmaceutical operations focused on cancer therapeutics [1][4]. Group 1: Warrants and Financial Details - The company entered into agreements to exercise warrants for a total of 928,596 shares of common stock, with exercise prices ranging from $2.00 to $3.00 per share [1]. - The exercise of 100,000 shares will occur at the existing price of $2.00, while 828,596 shares will be exercised at a reduced price of $2.485 per share [1]. - The gross proceeds from this exercise are expected to be around $2.5 million before deducting fees and expenses [1]. Group 2: New Warrants Issuance - In exchange for the immediate cash exercise of the warrants, holders will receive new unregistered warrants for an aggregate of up to 1,857,192 shares at an exercise price of $2.485 per share [3]. - The new warrants will have a term of twenty-four months for 1,538,596 shares and five years for 318,596 shares, effective upon the registration of the shares [3]. Group 3: Use of Proceeds - The company plans to utilize the net proceeds from the offering for working capital and other general corporate purposes [4]. Group 4: Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company that focuses on developing therapeutics using its INTASYL® gene silencing technology, particularly in the field of immuno-oncology [9]. - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial [9].

Core Viewpoint - Phio Pharmaceuticals is participating in the Sidoti Micro-Cap Virtual Investor Conference to present updates on its INTASYL® gene silencing technology and ongoing clinical trials for skin cancer treatment [1][3]. Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® technology aimed at eliminating cancer [1][5]. - The company's lead clinical program involves the INTASYL compound PH-762, which targets the PD-1 gene associated with various skin cancers [5][6]. Clinical Trials - The ongoing Phase 1b clinical trial (NCT 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, positioning it as a potential non-surgical treatment option for skin cancers [6]. Conference Details - The presentation by CEO Robert Bitterman is scheduled for May 22, 2025, at 10 AM ET, with one-on-one meetings with investors taking place on May 21-22, 2025 [2][3]. - Registration for the conference and meetings is free and open to all stakeholders and investors [2][3]. Sidoti Events Overview - Sidoti & Company, LLC has established Sidoti Events, LLC to enhance its conference business, focusing on small and microcap companies with market caps ranging from $200 million to $5 billion [4]. - Sidoti Events hosts eight investor conferences annually, providing corporate access and facilitating interactions between small and microcap issuers and investors [4].

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The company announced podium presentations for its lead INTASYL product candidates, PH-762 and PH-894, at the 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany [1] Product Candidates - PH-762 is an INTASYL siRNA compound targeting PD-1, currently undergoing evaluation in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, showing promising preclinical efficacy and favorable tolerability [2][4] - PH-894 selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, representing a novel approach to improve adoptive cell therapy [3] Conference Presentations - Melissa Maxwell, Phio's Director of Research and Program Management, will present on PH-762 during the Plenary Session 3, focusing on its preclinical advances and ongoing clinical evaluation [2] - PH-894 will be discussed in Plenary Session 11, highlighting its potential to increase NK cell activity for adoptive cell therapy [3]